Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
Diabetes Care · 01.08.2024 · 47 (8) · 1360-1369
DOI: 10.2337/dc24-0764 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 22.06.2024. Verfasst von Ildiko Lingvay und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine/Endocrinology and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dalla…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Glucagon-Like Peptides, Glycated Hemoglobin, Obesity. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novo Nordisk A/S.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). RESEARCH DESIGN AND METHODS In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo. The primary end point of first major adverse cardiovascular event (MACE) (cardiovascular mortality, nonfatal myocardial infarction, or stroke) was reduced by 20% with semaglutide versus placebo. Analysis of outcomes included first MACE, its individual components, expanded MACE (cardiovascular mortality, nonfatal myocardial infarction, or stroke; coronary revascularization; or hospitalization for unstable angina), a heart failure composite (heart failure hospitalization or urgent medical visit or cardiovascular mortality), coronary revascularization, and all-cause mortality by baseline HbA1c subgroup and categories of HbA1c change (<−0.3, −0.3 to 0.3, and >0.3 percentage points) from baseline to 20 weeks using the intention-to-treat principle with Cox proportional hazards. RESULTS Among 17,604 participants (mean age 61.6 years, 72.3% male), baseline HbA1c was <5.7% for 33.5%, 5.7% to <6.0% for 34.6%, and 6.0% to <6.5% for 31.9%. Cardiovascular risk reduction with semaglutide versus placebo was not shown to be different across baseline HbA1c groups and was consistent with that of the overall study for all end points, except all-cause mortality. Cardiovascular outcomes were also consistent across subgroups of HbA1c change. CONCLUSIONS In people with overweight or obesity and established atherosclerotic cardiovascular disease but not diabetes, semaglutide reduced cardiovascular events irrespective of baseline HbA1c or change in HbA1c. Thus, semaglutide is expected to confer cardiovascular benefits in people with established atherosclerotic cardiovascular disease who are normoglycemic at baseline and/or in those without HbA1c improvements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine/Endocrinology and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX.
- Institute of Cardiovascular Science, University College London, London, U.K.
- VA Puget Sound Health Care System and University of Washington, Seattle, WA.
- Novo Nordisk A/S, Søborg, Denmark.
- Division of Endocrinology and Diabetology, Department of Medicine, Medical University of Graz, Graz, Austria.
- TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
ORCID-Profile: Ildiko Lingvay, Lars Rydén, Michael Lehrke, Helen M Colhoun, Bertrand Cariou, Donna Ryan
Förderung
- Novo Nordisk A/S
Zitieren
APA
Lingvay, I., Deanfield, J., Kahn, S. E., Weeke, P. E., Toplak, H., Scirica, B. M., Rydén, L., Rathor, N., Plutzky, J., Morales, C., Lincoff, A. M., Lehrke, M., Jeppesen, O. K., Gajos, G., Colhoun, H. M., Cariou, B., Ryan, D., & SELECT Trial Investigators (2024). Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care, 47(8), 1360-1369. https://doi.org/10.2337/dc24-0764
Vancouver
Lingvay I, Deanfield J, Kahn SE, Weeke PE, Toplak H, Scirica BM, et al. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024;47(8):1360-1369. doi:10.2337/dc24-0764
BibTeX
@article{Lingvay2024,
author = {Lingvay, Ildiko and Deanfield, John and Kahn, Steven E and Weeke, Peter E and Toplak, Hermann and Scirica, Benjamin M and Rydén, Lars and Rathor, Naveen and Plutzky, Jorge and Morales, Cristobal and Lincoff, A Michael and Lehrke, Michael and Jeppesen, Ole Kleist and Gajos, Grzegorz and Colhoun, Helen M and Cariou, Bertrand and Ryan, Donna and SELECT Trial Investigators, SELECT Trial Investigators},
title = {Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT},
journal = {Diabetes Care},
year = {2024},
volume = {47},
number = {8},
pages = {1360--1369},
doi = {10.2337/dc24-0764}
}
EUVIMED